1.29%
1.01%
-1.34%
-10.82%
3.47%
-22.68%
38.62%
AI Spotlight on TECH
Company Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Market Data
| Last Price | 72.76 |
| Change Percentage | 1.29% |
| Open | 72.65 |
| Previous Close | 71.83 |
| Market Cap ( Millions) | 11561 |
| Volume | 900787 |
| Year High | 85.57 |
| Year Low | 61.16 |
| M A 50 | 74.05 |
| M A 200 | 74.41 |
Financial Ratios
| FCF Yield | 2.12% |
| Dividend Yield | 0.44% |
| ROE | 7.36% |
| Debt / Equity | 18.65% |
| Net Debt / EBIDTA | 60.76% |
| Price To Book | 5.39 |
| Price Earnings Ratio | 76.53 |
| Price To FCF | 47.18 |
| Price To sales | 9.87 |
| EV / EBITDA | 33.84 |
News
- Jan -30 - TECH Gears Up to Report Q2 Earnings: Here's What to Expect
- Jan -28 - FLEET UPDATE
- Jan -21 - EXEL vs. TECH: Which Stock Is the Better Value Option?
- Jan -21 - ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio
- Jan -21 - Bio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results
- Jan -13 - TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
- Jan -10 - Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
- Jan -08 - BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025
- Jan -08 - ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics
- Jan -07 - BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
- Jan -02 - BMRN or TECH: Which Is the Better Value Stock Right Now?
- Dec -23 - ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM
- Dec -23 - Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
- Dec -20 - BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
- Dec -19 - YSX TECH. CO., LTD Announces Closing of Its Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option
- Dec -19 - BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT
- Dec -18 - ScaleReady awards a G-Rex® Grant to Moonlight Bio
- Dec -17 - YSX TECH. CO., LTD Announces Pricing of Its Initial Public Offering
- Dec -12 - Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
- Dec -12 - BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Protein Sciences
Expected Growth : 6.5 %
What the company do ?
Protein Sciences from Bio-Techne Corporation is a leading provider of innovative protein analysis tools and services for life science research and drug discovery.
Why we expect these perspectives ?
Protein Sciences' 6.5% growth is driven by increasing demand for biologics, rising adoption of single-use technologies, and growing investments in cell and gene therapy research. Additionally, Bio-Techne's strategic acquisitions and expansion into emerging markets have contributed to the segment's growth.
Segment n°2 -> Diagnostics and Genomics
Expected Growth : 6.8 %
What the company do ?
Diagnostics and Genomics from Bio-Techne Corporation provides innovative solutions for molecular diagnostics, genomics, and gene expression analysis, enabling researchers to advance scientific discoveries and improve human health.
Why we expect these perspectives ?
Bio-Techne's Diagnostics and Genomics segment growth of 6.8% is driven by increasing demand for genetic testing, advancements in precision medicine, and growing adoption of molecular diagnostics in clinical settings. Additionally, the company's strategic acquisitions and investments in emerging technologies, such as next-generation sequencing, have expanded its product offerings and enhanced its market position.
Segment n°3 -> Intersegment
Expected Growth : 5.5 %
What the company do ?
Intersegment from Bio-Techne Corporation refers to the R&D Systems segment, a leading provider of life science reagents and instruments for research and diagnostics.
Why we expect these perspectives ?
Bio-Techne Corporation's 5.5% intersegment growth is driven by increasing demand for its life science and diagnostic products, particularly in the protein sciences and diagnostics segments. Strong sales of its ExoDx Prostate IntelliScore (EPI) test and growing adoption of its NanoString GeoMx Digital Spatial Profiler also contribute to this growth.
Bio-Techne Corporation Products
| Product Range | What is it ? |
|---|---|
| ProteinSimple | ProteinSimple is a line of protein analysis instruments and consumables that provide researchers with a comprehensive understanding of protein function and activity. |
| R&D Systems | R&D Systems is a leading provider of antibodies, assays, and reagents for life science research, offering a wide range of products for cell biology, immunology, and molecular biology applications. |
| Novus Biologicals | Novus Biologicals offers a comprehensive portfolio of antibodies, proteins, and other reagents for life science research, with a focus on emerging areas such as stem cell biology and gene editing. |
| Tocris Bioscience | Tocris Bioscience is a leading provider of small molecules and biochemicals for life science research, offering a wide range of products for pharmacology, neuroscience, and cancer research applications. |
| Advanced Cell Diagnostics (ACD) | ACD is a pioneer in the field of RNA in situ hybridization, offering a range of products and services for the detection and analysis of RNA biomarkers in tissue samples. |
| Exosome Diagnostics | Exosome Diagnostics is a leading provider of exosome-based diagnostics and research tools, enabling the detection and analysis of exosomal RNA and protein biomarkers in biofluids. |
Bio-Techne Corporation's Porter Forces
Threat Of Substitutes
Bio-Techne Corporation operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Bio-Techne Corporation's customers are primarily researchers and scientists who rely on the company's products for their research and development. The bargaining power of customers is low due to the specialized nature of the products.
Bargaining Power Of Suppliers
Bio-Techne Corporation relies on a few key suppliers for raw materials and equipment. The bargaining power of suppliers is medium due to the availability of alternative suppliers in the market.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. The threat of new entrants is low due to these barriers.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. The intensity of rivalry is high due to the competitive nature of the industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 18.79% |
| Debt Cost | 3.95% |
| Equity Weight | 81.21% |
| Equity Cost | 10.06% |
| WACC | 8.92% |
| Leverage | 23.14% |
Bio-Techne Corporation : Quality Control
Bio-Techne Corporation passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDYA | IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product … |
| INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
| ALNY | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, … |
| ADMA | ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. … |
| BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bio-Techne
A-Score
1-Year Total Return ->
🥈
ADMA Biologics
A-Score
1-Year Total Return ->
🥉
Insmed
A-Score
1-Year Total Return ->
4
Alnylam Pharmaceuticals
A-Score
1-Year Total Return ->
5
BridgeBio Pharma
A-Score
1-Year Total Return ->
6
